<?xml version="1.0" encoding="UTF-8"?>
<p>2n also resulted in being more active in in vitro assays against HTNV than two orthohantavirus candidate drugs: ETAR (1-beta-d-ribofuranosyl-3-ethynyl-[1,2,4] triazole) (EC
 <sub>50</sub> = 10 µM) and Favipiravir (EC
 <sub>50</sub> =150.8 μM), respectively 2- and 37-fold more potent [
 <xref rid="B13-viruses-12-00122" ref-type="bibr">13</xref>,
 <xref rid="B23-viruses-12-00122" ref-type="bibr">23</xref>].
</p>
